ENDONOVO THERAPEUTICS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
ENDONOVO THERAPEUTICS, INC. (ENDV) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$5.50 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-19.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2021-11-19
- ENDONOVO THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-09-30 was -$1.50M.
- ENDONOVO THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-09-30 was -$1.07M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month |
|---|---|---|---|
| 2021-09-30 | -$1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-19 | -$5.50M 10-Q · filed 2021-11-19 | |
| 2021-06-30 | -$4.00M 10-Q · filed 2021-08-23 | ||
| 2020-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-19 | $1.63M 10-Q · filed 2021-11-19 | |
| 2020-06-30 | $2.70M 10-Q · filed 2021-08-23 |